Latest News and Press Releases
Want to stay updated on the latest news?
-
BRUSSELS, Belgium, Aug. 26, 2005 (PRIMEZONE) -- UCB today announces the divestment of Celltech Manufacturing Services Ltd., in Ashton, U.K., a UCB subsidiary carrying out contract manufacturing. The...
-
Brussels, Belgium, August 26, 2005 - UCB today announces the divestment of Celltech Manufacturing Services Ltd, in Ashton, UK, a UCB subsidiary carrying out contract manufacturing. The...
-
Novel Antibody Targeting the VEGF Receptor-2 to Enter Phase II Clinical Development Brussels and New York - August 16, 2005 - UCB and ImClone Systems Incorporated (NASDAQ: IMCL) announced...
-
Brussels (Belgium) August 1st, 2005: UCB today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion,...
-
BRUSSELS, Belgium, July 27, 2005 (PRIMEZONE) -- UCB (Pink Sheets:UCBJF) today announced its results for the six months ended June 30, 2005. Roch Doliveux, CEO of UCB comments: "In the first half of...
-
Le bénéfice opérationnel (EBIT) progresse de 16% (tel que rapporté) Le bénéfice net augmente de 232% en tenant compte de la plus-value de € 470 millions sur la vente des activités...
-
Reported operating profit (EBIT) up 16% Net profit up 232% including capital gain of € 470 million on sale of discontinued businesses On a like for like basis, revenues up 11%, EBIT up 19%,...
-
Winst vóór interest en belastingen (EBIT) gestegen met 16% Nettowinst gestegen met 232%, inclusief een meerwaarde van € 470 miljoen op de verkoop van beëindigde bedrijfsactiviteiten Op...
-
Reported operating profit (EBIT) up 16% Net profit up 232% including capital gain of € 470 million on sale of discontinued businesses On a like for like basis, revenues up 11%, EBIT up 19%,...
-
Winst vóór interest en belastingen (EBIT) gestegen met 16% Nettowinst gestegen met 232%, inclusief een meerwaarde van € 470 miljoen op de verkoop van beëindigde bedrijfsactiviteiten Op...